Roivant Sciences Financials - Benzinga

Roivant Sciences Ltd

ROIVNASDAQ

Trade with Public

Trade with Public

$36.09

-0.73-1.98%

最終更新: Sep 24, 12:05 PM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Roivant Sciences Financials

Roivant Sciences (ROIV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of $(0.25) per share from

Benzinga Newsdesk

S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today

U.S. stocks halt a three-day slide as oil tumbles 5% on revived Iran truce hopes, easing inflation fears ahead of Nvidia's results after the close.

Piero Cingari

Earnings Scheduled For May 20, 2026

Benzinga Insights

PRO
Roivant Sciences Q4 Adj. EPS $(0.27) Beats $(0.34) Estimate

Benzinga Newsdesk

PRO
Roivant Sciences Q4 Sales $2.520M Miss $3.820M Estimate

Benzinga Newsdesk

Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters

Roivant shares surged after its skin disease drug brepocitinib showed strong Phase 2 results, with high response rates, early benefits, and no serious safety issues.

Vandana Singh

© 2026 Benzinga | All Rights Reserved